BofA raised the firm’s price target on Akero Therapeutics (AKRO) to $64 from $63 and keeps a Buy rating on the shares. Akero’s Q1 print was “unsurprisingly quiet,” taking a backseat to other updates as FGF21 agonist efruxifermin continues to advance for fatty liver disease, the analyst tells investors in a post-earnings note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Biotech Alert: Searches spiking for these stocks today
- Akero Therapeutics up 16% after Street Insider report on sale being considered
- Akero Therapeutics exploring potential sale after approach, Street Insider says
- Akero Therapeutics’ Promising Developments and Financial Strength Support Buy Rating with $73 Price Target
- Akero Therapeutics price target lowered to $78 from $80 at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue